Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Actinic keratosis and field change

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise individual actinic keratoses and field cancerisation, identify possible invasive SCC, choose lesion- or field-directed treatment and support long-term ultraviolet protection and surveillance.

  • Actinic keratosis is a rough, sandpaper-like keratotic macule or papule on chronically ultraviolet-exposed skin and may be easier to feel than see.
  • Field change means multiple lesions plus background mottling, atrophy and telangiectasia across a sun-damaged anatomical area.
  • Biopsy a tender, indurated, rapidly enlarging, bleeding, ulcerated, thick or treatment-resistant lesion to exclude invasive SCC.
  • Observation with protection is reasonable for selected thin asymptomatic lesions in lower-risk patients when follow-up and safety-netting are reliable.
  • Cryotherapy is lesion directed; topical 5-fluorouracil, imiquimod, diclofenac, tirbanibulin or photodynamic therapy can address a field according to site and licence.
  • For 5-fluorouracil 5% cream, a common licensed field regimen is once or twice daily for three to four weeks, with site-specific specialist directions.
  • Explain the expected sequence of redness, soreness, erosion and healing before field treatment and supply a stop and contact plan.
  • Use shade, clothing, hats and broad-spectrum sunscreen while avoiding messages that imply past ultraviolet damage can be reversed completely.

Key red flags

Induration, tenderness, rapid growth, ulceration, bleeding, a thick cutaneous horn, lip involvement, treatment resistance or immune suppression raises invasive SCC concern and requires urgent diagnostic review.

Invasive warning

New pain, induration, rapid growth, ulceration, bleeding or treatment resistance requires urgent biopsy for SCC.

Investigation priorities

01
Full field examinationFirst step

Map lesion burden, background damage and any focus suspicious for invasion.

Management branches

Few discrete lesionsTreat or observe individually

A small number of typical thin lesions has no invasive warning and host risk is low.

  1. Discuss observation versus lesion-directed cryotherapy based on symptoms, site and preference.
  2. For cryotherapy, obtain consent for pain, blister, pigment change and scar and use anatomy-appropriate freeze technique.
  3. Review non-clearance or focal thickening and biopsy rather than repeatedly freezing an uncertain lesion.

Key medicines

Fluorouracil 5% creamApply a thin layer once or twice daily to the precisely defined actinic field for three to four weeks, or as directed for the anatomical site.Avoid pregnancy, eyes and mucosa; review severe inflammation, infection and dihydropyrimidine dehydrogenase deficiency risk, wash hands and follow site-specific specialist instructions.
Open full textbook →Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists actinic keratosesRecognition, SCC warnings, treatment and prevention.
  • Efudix 5% cream SmPCFluorouracil field regimen, reactions and contraindications.
  • NICE NG12 suspected cutaneous SCC referralUrgent escalation of suspected invasive SCC.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom